Join our daily newsletter At The Bell to receive exclusive market insights
- Drug development company, Neuroscientific Biopharmaceuticals (NSB) has signed a manufacturing agreement with leading Japanese company, Mitsubishi Corporation
- Under the agreement, Mitsubishi’s invested company PeptiStar will undertake feasibility and analytical services for large-scale manufacturing of the EmtinB drug for future clinical programs
- EmtinB is currently being developed as a treatment for Alzheimer’s disease
- NSB remains steady on the market today, trading for 18¢ per share
Drug development company, Neuroscientific Biopharmaceuticals (NSB) has signed a manufacturing agreement with leading Japanese company, Mitsubishi Corporation.
Under the agreement, Mitsubishi’s invested company PeptiStar will undertake feasibility and analytical services for large-scale manufacturing of the EmtinB drug for future clinical programs.
NSB expects this to begin in the second half of 2020.
EmtinB is currently being developed as a treatment for neurodegenerative dementia and Alzheimer’s disease.
CEO and Managing Director Matt Liddelow is pleased with the agreement.
“NSB is excited to be working with PeptiStar and its globally recognized parent company, Mitsubishi,” he said.
“These companies will add significant peptide manufacturing expertise to NSB’s clinical development programs and we hope this agreement will be the first step towards a long-term manufacturing partnership with Mitsubishi and PeptiStar,” he added.
Recently, NSB announced significant positive results in a novel treatment for Multiple Sclerosis.
NSB remains steady on the market today, trading for 18¢ per share at 1:37 pm AEST.
